We are live on
!
Find out more
NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.23B
1-Year Est. Return
81.32%
This Fund
S&P 500
This Quarter
Est. Return
+21.59%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$2.01B
AUM Growth
+$159M
(+8.5%)
Cap. Flow
-$108M
Cap. Flow
% of AUM
-5.35%
Top 10 Holdings %
Top 10 Hldgs %
68.56%
Holding
39
New
1
Increased
7
Reduced
7
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ZBIO
Zenas BioPharma
ZBIO
|
+$20.7M |
| 2 |
Viridian Therapeutics
VRDN
|
+$6.29M |
| 3 |
Celldex Therapeutics
CLDX
|
+$4.33M |
| 4 |
4D Molecular Therapeutics
FDMT
|
+$1.66M |
| 5 |
MRUS
Merus
MRUS
|
+$1.31M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$38.5M |
| 2 |
Salesforce
CRM
|
+$28.6M |
| 3 |
Brookfield
BN
|
+$18.4M |
| 4 |
Vaxcyte
PCVX
|
+$18M |
| 5 |
Edgewise Therapeutics
EWTX
|
+$15.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 57.87% |
| 2 | Financials | 10.69% |
| 3 | Technology | 10.64% |
| 4 | Consumer Discretionary | 2.64% |
| 5 | Communication Services | 2.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ZBIO
26
Zenas BioPharma
ZBIO
$2.05B
| $19.5M | 0.97% |
+1,150,000
| New | +$20.7M |
|
|
27
4D Molecular Therapeutics
FDMT
$562M
| $16.2M | 0.81% |
1,500,000
+100,000
| +7% | +$1.66M |
|
|
BPMC
28
DELISTED
Blueprint Medicines
BPMC
| $16.2M | 0.8% |
175,000
| – | – |
|
|
VERV
29
DELISTED
Verve Therapeutics
VERV
| $11.6M | 0.58% |
2,400,000
| – | – |
|
30
Lexeo Therapeutics
LXEO
$378M
| $10.1M | 0.5% |
1,122,581
-327,919
| -23% | -$3.91M |
|
31
Kyverna Therapeutics
KYTX
$484M
| $9.05M | 0.45% |
1,850,000
+100,000
| +6% | +$771K |
|
32
Metagenomi Therapeutics
MGX
$46.3M
| $3.91M | 0.19% |
1,800,000
| – | – |
|
|
IOBT
33
DELISTED
IO Biotech
IOBT
| $3.52M | 0.17% |
3,354,449
-1,075,000
| -24% | -$1.35M |
|
34
AbCellera Biologics
ABCL
$2.12B
| $2.93M | 0.15% |
1,126,915
| – | – |
|
35
Marqeta
MQ
$1.66B
| $2.17M | 0.11% |
110,390
| – | – |
|
|
DMRA
36
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
| $1.21M | 0.06% |
99,913
+1
| +0% | +$13 |
|
37
Spero Therapeutics
SPRO
$73M
| $628K | 0.03% |
468,902
| – | – |
|
|
38
Apple
AAPL
$4.57T
| – | – |
-182,960
| Closed | -$38.5M |
|
|
MORF
39
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| – | – |
-375,000
| Closed | -$12.8M |
|
Similar funds
MP
FLII
IC
IA
HTHT
BCP
SPC
SC
Novo Holdings A/S's Q3 2024 Portfolio in Review
As of Q3 2024, Novo Holdings A/S held 39 positions worth $2.01B, up 8.5% from $1.85B the previous quarter. Its ten largest holdings account for 69% of the portfolio.
Novo Holdings A/S withdrew a net $108M in Q3 2024, closing 2 positions and reducing 7 holdings. Its most notable exit was Apple, an estimated $38.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 58% of assets, up from 53% a quarter earlier, followed by Financials and Technology.
Against the trend, Novo Holdings A/S opened a new position in Zenas BioPharma worth $19.5M.
- Novo Holdings A/S's largest Q3 2024 buy was Zenas BioPharma: 1,150,000 shares worth $19.5M.
- Novo Holdings A/S added most to Viridian Therapeutics in Q3 2024, an estimated $6.29M increase.
- Novo Holdings A/S's biggest Q3 2024 reduction was Salesforce, cutting an estimated $28.6M.
- Novo Holdings A/S fully exited Apple in Q3 2024, selling an estimated $38.5M.
- Novo Holdings A/S's ten largest holdings make up 69% of its $2.01B portfolio in Q3 2024.
- Novo Holdings A/S opened 1 new position and closed 2 in Q3 2024.
- Novo Holdings A/S's portfolio value rose 8.5% quarter-over-quarter to $2.01B.
Based on Novo Holdings A/S's 13F filing for Q3 2024, filed 24 Oct 2024.